Alexion Pharmaceuticals

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The Company is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders.
Company Growth (employees)
Type
Public
HQ
New Haven, US
Founded
1992
Size (employees)
3,121 (est)
Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US

Alexion Pharmaceuticals Office Locations

Alexion Pharmaceuticals has offices in New Haven, Zürich, Barcelona, London and in 26 other locations
New Haven, US (HQ)
100 College St
Zürich, CH
30 Giesshübelstrasse
Show all (31)

Alexion Pharmaceuticals Financials and Metrics

Alexion Pharmaceuticals Financials

Alexion Pharmaceuticals's revenue was reported to be $3.1 b in FY, 2016
USD

Revenue (Q3, 2017)

859 m

Gross profit (Q3, 2017)

702 m

Gross profit margin (Q3, 2017), %

82%

Net income (Q3, 2017)

78 m

EBIT (Q3, 2017)

80 m

Market capitalization (08-Dec-2017)

25.8 b

Cash (30-Sep-2017)

550 m

EV

25.4 b
Alexion Pharmaceuticals's current market capitalization is $25.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.6 b2.2 b2.6 b3.1 b

Revenue growth, %

44%17%18%

Cost of goods sold

233.1 m258 m

Gross profit

2.4 b2.8 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

636.2 m666.6 m701 m753.1 m799.1 m870 m912 m859 m

Cost of goods sold

51.4 m32.9 m39.6 m51.9 m69.4 m52 m54.1 m59 m60.6 m71.1 m69 m84 m157 m

Gross profit

584.2 m612.6 m642.1 m692.5 m728 m801 m828 m702 m

Gross profit Margin, %

92%92%92%92%91%92%91%82%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

529.9 m944 m1 b966 m

Accounts Receivable

650 m

Inventories

102.6 m176.4 m289.9 m375 m

Current Assets

2.2 b2.8 b2.4 b2.6 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

910.4 m528.3 m612 m752.2 m916.8 m1.3 b1.2 b710.2 m597.6 m762 m713 m542 m550 m

Accounts Receivable

405 m429 m440.7 m436.5 m479.9 m535.8 m512.3 m586.2 m609.3 m676.8 m660 m710 m705 m

Inventories

105.2 m126.2 m144.9 m140 m174.5 m234.3 m236.5 m294 m329.8 m363.1 m396 m410 m441 m

Current Assets

1.9 b2.2 b2.3 b2.6 b2.9 b2.5 b2.5 b2.1 b2.4 b2.6 b2.7 b2.8 b2.9 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

252.9 m656.9 m144.4 m399 m

Depreciation and Amortization

28.7 m46.9 m166.6 m396 m

Accounts Receivable

(120 m)(28 m)(120 m)(122 m)

Inventories

126 k(67 m)(88 m)(84 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

93.8 m159.4 m166.5 m177.7 m91.3 m261.5 m77.8 m92.2 m207.1 m306.6 m170 m335 m413 m

Depreciation and Amortization

23.1 m72.9 m96.8 m194.6 m295.3 m99 m201 m311 m

Accounts Receivable

(109 m)(91 m)(37.3 m)(65.2 m)(129.9 m)(3 m)(46 m)(35 m)

Inventories

144.9 m140 m174.5 m4.7 m(7.4 m)(3.8 m)(39 m)(72.2 m)(19 m)(33 m)(69 m)
USDY, 2017

EV/EBIT

317.1 x

EV/CFO

29.6 x

Revenue/Employee

275.2 k

Financial Leverage

1.5 x
Show all financial metrics

Alexion Pharmaceuticals Market Value History

Alexion Pharmaceuticals Median Salaries

Source: 33 public H-1B filings from Alexion Pharmaceuticals

Alexion Pharmaceuticals's Web-traffic and Trends

Alexion Pharmaceuticals Online and Social Media Presence

Alexion Pharmaceuticals Company Life and Culture

You may also be interested in